ChemBriefKura Oncology launches diabetes-focused Caspian Therapeutics
Kura Oncology launched Caspian Therapeutics with $50 million to develop menin inhibitors for diabetes and cardiometabolic diseases. Backed by Eli Lilly and the T1D Fund, Kura retains a 50% stake in th
cen · 2026-09-09 00:00